Prescription Drug Silodosin Recalled Due to Subpotency and Out-of-Specification Impurity
AvKARE is recalling Silodosin 8mg capsules nationwide due to subpotent drug levels and out-of-specification impurity found in stability testing. The affected lot is BC20223A, expiring March 31, 2025.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall involving subpotent drug levels marginally below specification, with no reported illnesses or injuries. The hazard is theoretical quality control failure without reported acute harm.
Plain-English summary
AvKARE is recalling Silodosin 8mg capsules (NDC 42291-778-90) nationwide. The recall affects 1,266 bottles of lot BC20223A, which expire on March 31, 2025. Silodosin is a prescription medication used to treat benign prostatic hyperplasia.
The recall was initiated due to quality control findings in stability testing. Testing of an 18-month stability sample revealed that the drug assay (active ingredient content) measured 94.9%, below the required specification of 95.0% to 105.0%. Additionally, a dehydro impurity was detected at 0.654% in the same sample.
Consumers and healthcare providers should check whether they have this product. The affected lot number is BC20223A.
Consumers should contact their healthcare provider or pharmacist before discontinuing the medication. AvKARE and healthcare providers can provide information about alternatives or replacements.
The recalled product
- Product
- SILODOSIN (SILODOSIN)
- Brand
- SILODOSIN
- Manufacturer
- AvKARE
- Category
- Drug — Prescription
- Hazard
- subpotency
- dehydro-impurity
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lot#: BC20223A
- Exp. March 31
- 2025.
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereErythromycin Tablets Recalled for Impurity Above Acceptable Limits
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- ModeratePrimidone Tablets Recalled Due to API Cross-Contamination
FDA (Drugs) · 2026-05-27
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27